Top Stock Reports for Eli Lilly, AbbVie & Gilead Sciences

Monday, December 9, 2024The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie Inc. (ABBV) and Gilead Sciences, Inc. (GILD), as well as two micro-cap stocks, Air T, Inc. (AIRT) and Fossil Group, Inc. (FOSL). These research reports have been hand-picked from roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>Eli Lilly’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+41.5% vs. +12.8%), reflecting the strong demand for Mounjaro and Zepbound. The company has received approvals for several new drugs like Kisunla, Omvoh and Jaypirca. Lilly is also making rapid pipeline progress in areas like obesity, diabetes and Alzheimer’s.However, declining sales of Trulicity is a major headwind..(You can read the full research report on Eli Lilly here >>>)AbbVie shares have underperformed the Zacks Large Cap Pharmaceuticals industry over the past two years (+6.6% vs. +17.7%). The Zacks analyst believes that the company faces several near-term headwinds like Humira’s biosimilar erosion, increasing competitive pressure on Imbruvica and slow market growth trend for Juvederm fillers in the United States and China.Yet, Skyrizi and Rinvoq are performing extremely well, bolstered by approvals in new indications, which should support top-line growth in the next few years. AbbVie has several early/mid-stage candidates that have the potential to drive long-term growth.(You can read the full research report on AbbVie here >>>)Shares of Gilead Sciences have outperformed the Zacks  Medical – Biomedical and Genetics industry over the last six months (+41.2% vs. -1.8%). Per the Zacks analyst, the company’s efforts to develop better HIV treatments are commendable. Lenacapavir’s data readout impresses investors. Substantial growth in Yescarta and Tecartus, along with the strong uptake of Trodelvy, has strengthened its oncology franchise.However, recent pipeline setbacks weigh on Gilead.(You can read the full research report on Gilead Sciences here >>>)Air T’s shares have outperformed the Zacks Transportation – Air Freight and Cargo  industry over the past year (+34.1% vs. -11.6%). The Zacks analyst believes that the company’s overnight Air Cargo segment, primarily serving FedEx, is a major growth driver, aided by fleet expansion and stable demand. Its asset-light model lowers operational risk. Strength in air cargo and commercial jet engines and parts and a sole-source deicer supply contract with the U.S. Air Force aid.Yet, rising operating losses, inventory write-downs, high debt and a shrinking order backlog in Ground Equipment Sales signal challenges and potential pressure on future performance. Joint ventures (JVs) in aircraft asset management offer upside potential. Key customer dependence and seasonal risks add to concerns.(You can read the full research report on Air T here >>>)Fossil Group’s shares have outperformed the Zacks Retail – Apparel and Shoes  industry over the past year (+61.5% vs. +39.5%). The Zacks analyst believes that SKU rationalization, pricing adjustments and exiting the lower-margin smartwatch category under the TAG Plan have benefited the company. Strategic exits from the smartwatch category and store closures have optimized operations, contributing to gross margin gains.Yet, declining net sales due to strategic shifts, pressure on licensed watch brands and high debt levels present ongoing challenges.(You can read the full research report on Fossil Group here >>>)Other noteworthy reports we are featuring today include Intel Corporation (INTC), Marvell Technology, Inc. (MRVL) and Coinbase Global, Inc. (COIN).Director of ResearchSheraz MianNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>Today's Must ReadLilly's (LLY) Mounjaro, Zepbound Key to Sales GrowthAbbVie's (ABBV) Skyrizi, Rinvoq Key to Top-Line GrowthHIV, Trodelvy Fuel Gilead (GILD) Amid Pipeline SetbacksFeatured ReportsInvestments Aid Edison International (EIX), Rising Costs AilPer the Zacks analyst, systematic capital investment boosts Edison International's infrastructure and customer reliability. Yet, rising wildfire related charges are hurting its bottom line.EOG Resources' (EOG) Untapped Shale Drilling Potential AidsPer the Zacks analyst, EOG excels in shale drilling and free cash flow conversion with untapped opportunities, but rising lease and well expenses could lay pressure on margins amid inflation.Intel (INTC) Benefits From Product Innovation & Solid AI TractionPer the Zacks analyst, focus on developing cutting-edge AI chips to meet the rising demand for AI PCs will likely drive Intel's top line. Strength in IoT and ADAS domains is a tailwind.Solid Strategic Execution Aids Labcorp (LH), Cost Woes StayPer the Zacks analyst, Labcorp gains strategically by being a top partner with health systems and using data and technology to bring key services and capabilities. Yet, rising costs may dent growth. Unit Expansion & Robust Digitalization Aid Yum China (YUMC)Per the Zacks analyst, Yum China benefits from menu innovation, unit expansion and digitalization. Focus on the acceleration of franchise development to unlock additional opportunities bodes well. Portfolio Growth Aids SBA Communications (SBAC) Amid 5G HypePer the Zacks Analyst, SBA Communications will likely see portfolio growth on rising demand and adoption of data-driven mobile devices and applications, though customer concentration is a risk.Paychex (PAYX) Gains on Flexible Portfolio Despite ExpensesPer the Zacks analyst, Paychex's ability to meet clients' HR and payroll needs through a comprehensive and flexible service portfolio benefits its top line. Rising expenses are concerning.New UpgradesSolid Demand Across Data Center Market Aid Marvell (MRVL)Per the Zacks Analyst, Marvell is growing on solid momentum in electro-optics products, custom silicon, storage and switch divisions, which are driving the Data Center end-market revenues.Coinbase (COIN) Boasts Revenue Growth, Solid Balance SheetPer the Zacks analyst, higher transaction revenues, subscription and services revenues, growth in crypto assets should drive Coinbase revenues. Its solid balance sheet provides financial flexibility.Improved Menu Pricing & Expansion Efforts Aid Brinker (EAT)Per the Zacks analyst, Brinker is benefiting from effective marketing and pricing strategies. Also, focus on menu adjustments along with remodeling and expansion initiatives bode well.New DowngradesHigh Debt and Oil Price Volatility Ails W&T Offshore (WTI)Per the Zacks analyst, W&T Offshore's exposure to extreme volatility in oil and natural gas prices could negatively impact its profitability. Its high reliance on debt adds further risk.Weaker Demand, Rising SG&A Expenses Ail Genuine Parts (GPC)Per the Zacks analyst, weaker-than-anticipated customer demand is likely to hurt Genuine Parts' top- and bottom-line growth in 2024. Rising SG&A expenses are denting the company???s operating profits.Soft North American Segment to Hurt Signet (SIG) Top LinePer the Zacks analyst, the North American segment experienced a decline, driven by challenges in maintaining customer transactions. Sales in this segment fell 2.3% in the third quarter.Free Today: Profiting from The Future’s Brightest Energy SourceThe demand for electricity is growing exponentially. At the same time, we’re working to reduce our dependence on fossil fuels like oil and natural gas. Nuclear energy is an ideal replacement.Leaders from the US and 21 other countries recently committed to TRIPLING the world’s nuclear energy capacities. This aggressive transition could mean tremendous profits for nuclear-related stocks – and investors who get in on the action early enough.Our urgent report, Atomic Opportunity: Nuclear Energy's Comeback, explores the key players and technologies driving this opportunity, including 3 standout stocks poised to benefit the most.Download Atomic Opportunity: Nuclear Energy's Comeback free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intel Corporation (INTC): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Marvell Technology, Inc. (MRVL): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Coinbase Global, Inc. (COIN): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks